>
Bioxyne logo

BXN - Bioxyne Share Price

A$0.017 0.0  0.0%

Last Trade - 5:27am

Sector
Healthcare
Size
Micro Cap
Market Cap £6.04m
Enterprise Value £5.10m
Revenue £1.18m
Position in Universe 1707th / 1896
Bullish
Bearish
Unlock BXN Revenue
Momentum
Relative Strength (%)
1m +50.0%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -29.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
1.49 1.92 1.79 1.99 2.13 2.26 +8.7%
-30.0 +11.4
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, BioxyneLtd revenues decreased 10% to A$1.2M. Net loss increasedfrom A$195K to A$432K. Revenues reflect a decrease indemand for the Company's products and services due tounfavorable market conditions. Higher net loss reflectsOther income decrease of 40% to A$44K (income), General andadministration increase of 9% to A$168K (expense), Directorfees increase of 7% to A$129K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BXN Revenue Unlock BXN Revenue

Net Income

BXN Net Income Unlock BXN Revenue

Normalised EPS

BXN Normalised EPS Unlock BXN Revenue

PE Ratio Range

BXN PE Ratio Range Unlock BXN Revenue

Dividend Yield Range

BXN Dividend Yield Range Unlock BXN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BXN EPS Forecasts Unlock BXN Revenue
Profile Summary

Bioxyne Limited is an Australia-based bio-technology company engaged in the development of, manufacture, marketing and distribution of consumer dietary supplements based on the probiotic strain of Lactobacillus Fermentum PCC. The Company has an agreement to manufacture, market, supply and distribute its probiotic strain for over the counter dietary supplement products. Its segments include Probiotics and Other. It focuses on immune health and immunotherapeutic products. The Company's focus is on its probiotic business and product Lactobacillus fermentum PCC. The Company holds an interest in Mariposa Health Limited, a pharmaceutical development company with a focus on Congestive and Obstructive Pulmonary Disease (COPD).

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated September 23, 1998
Public Since December 14, 2000
No. of Shareholders: n/a
No. of Employees: 16
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 640,145,398
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BXN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BXN
Upcoming Events for BXN
Frequently Asked Questions for Bioxyne
What is the Bioxyne share price?

As of 5:27am, shares in Bioxyne are trading at A$0.017, giving the company a market capitalisation of £6.04m. This share price information is delayed by 15 minutes.

How has the Bioxyne share price performed this year?

Shares in Bioxyne are currently trading at A$0.017 and the price has moved by 54.55% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bioxyne price has moved by 18.46% over the past year.

What are the analyst and broker recommendations for Bioxyne?

There are no analysts currently covering Bioxyne.

When will Bioxyne next release its financial results?

Bioxyne is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Bioxyne dividend yield?

Bioxyne does not currently pay a dividend.

Does Bioxyne pay a dividend?

Bioxyne does not currently pay a dividend.

When does Bioxyne next pay dividends?

Bioxyne does not currently pay a dividend.

How do I buy Bioxyne shares?

To buy shares in Bioxyne you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bioxyne?

Shares in Bioxyne are currently trading at A$0.017, giving the company a market capitalisation of £6.04m.

Where are Bioxyne shares listed? Where are Bioxyne shares listed?

Here are the trading details for Bioxyne:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: BXN
What kind of share is Bioxyne?

Based on an overall assessment of its quality, value and momentum, Bioxyne is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Bioxyne share price forecast 2021?

We were not able to load any forecast data for Bioxyne.

How can I tell whether the Bioxyne share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioxyne. Over the past six months, the relative strength of its shares against the market has been 16%. At the current price of A$0.017, shares in Bioxyne are trading at 33.36% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bioxyne PE Ratio?

We were not able to find PE ratio data for Bioxyne.

Who are the key directors of Bioxyne?

Bioxyne's management team is headed by:

Patrick Ford - NED
Anthony Ho - CHM
Guy Robertson - CFO
Nam Hoat Chua - CEO
Peter Hughes-Hallett - NED
Who are the major shareholders of Bioxyne?

Here are the top five shareholders of Bioxyne based on the size of their shareholding:

VIG Ltd. Corporation
Percentage owned: 12.58% (80.6m shares)
Chua (Nam Hoat) Individual Investor
Percentage owned: 8.99% (57.6m shares)
Ng (Peng Hyang) Individual Investor
Percentage owned: 8.05% (51.5m shares)
Ho (Anthony Peng) Individual Investor
Percentage owned: 4.34% (27.8m shares)
Waitara Trustees Ltd. Corporation
Percentage owned: 3.91% (25.0m shares)
Similar to BXN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.